In patients who require apicectomy and retrograde obturation, which filling material is most effective?
Commentary
Retrograde root canal filling after apicectomy is regarded as an important procedure to secure the seal of the apical end of root canals inaccessible to orthograde endodontic filling. For many years, amalgam has been accepted as the material of choice for retrofilling in endodontic surgery. Recently, many researchers have questioned the suitability of amalgam as a retroseal because concern over free mercury and poor results in leakage studies carried out in vitro.
The importance of this review article was its comparison of the clinical outcome of the use of different retroseal materials, not just within laboratory studies.
Many researchers look for alternative materials for retrofilling, such as glass ionomer cement, gold foil, EBA cement or cyanoacrylate. Many of these studies for retrofilling material were carried out only in vitro, as illustrated here in the result of the review authors' Medline search. Of 324 papers initially identified, 108 papers reported in vitro studies, whereas in vivo studies were limited to only 32. This made it difficult to evaluate the clinical significance of new retrofilling materials in the clinical setting.
Both the efficacy of newly introduced retrofilling materials and the success rate of amalgam retrofilling as a control therapy was distributed very broadly, at 51.9-95.7% in the extracted papers. This heterogeneity made it difficult to combine the results in a metaanalysis and to interpret the result clearly. The wide deviation of success rates might be due to the lack of standardisation of surgical procedures and inclusion/exclusion criteria of cases.
The number-needed-to-treat (NNT) was mainly used in this review to compare the clinical significance of each material. This is a useful index with which to demonstrate the number of teeth that need to be filled with experimental material to prevent one additional failure. When I recalculated the NNT using the numbers that appeared in the first RCT, 1 the NNT was 57, suggesting amalgam was slightly more effective than glass ionomer cement. The result from another RCT 2 was that the success rates for amalgam and glass ionomer were exactly the same, meaning the NNT did not converge. Taking account of results from other clinical studies, the variation within the research was too large. Even for the most investigated material, glass ionomer cement, it is hard to conclude whether it is superior or equivalent to amalgam. For the various other materials that have been introduced, clinical evidence is even more limited. Even MTA (mineral trioxide aggregate), widely accepted as a promising retrofilling material in the clinical setting in recent times, was supported only with case reports and in vitro studies. Further research is needed because no controlled trials have been performed.
Clinical superiority of retrofilling materials can be most effectively demonstrated by clinical studies. There is not enough evidence to recommend alternative retrofilling materials to amalgam at the present time.
Practice point
At present the evidence is not strong enough to recommend a move from amalgam.
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